|
ZNF200 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.12830000021225E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.59400000000676E-05 |
| Normal-vs-Stage2 |
1.563710E-03 |
| Normal-vs-Stage3 |
3.21330000052633E-07 |
| Normal-vs-Stage4 |
5.96810000308423E-08 |
| Stage1-vs-Stage2 |
8.777600E-01 |
| Stage1-vs-Stage3 |
4.074300E-02 |
| Stage1-vs-Stage4 |
1.262440E-02 |
| Stage2-vs-Stage3 |
2.418400E-01 |
| Stage2-vs-Stage4 |
8.161500E-02 |
| Stage3-vs-Stage4 |
4.165000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.27310000000536E-06 |
| Normal-vs-AfricanAmerican |
8.421500E-04 |
| Normal-vs-Asian |
1.436350E-03 |
| Caucasian-vs-AfricanAmerican |
6.444600E-01 |
| Caucasian-vs-Asian |
6.036200E-01 |
| AfricanAmerican-vs-Asian |
4.502600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.71390000000849E-06 |
| Normal-vs-Female |
1.03900000003598E-06 |
| Male-vs-Female |
8.554800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.00139999999771E-05 |
| Normal-vs-Age(41-60Yrs) |
4.3247000000024E-06 |
| Normal-vs-Age(61-80Yrs) |
7.81090000012696E-07 |
| Normal-vs-Age(81-100Yrs) |
5.855700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.855200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.162000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.835400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.309200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.413800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.063800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.507740E-02 |
| Classical-VS-Follicular |
1.406230E-02 |
| Classical-VS-Other |
5.171400E-01 |
| Classical-VS-Normal |
9.7647000000034E-05 |
| Tall-VS-Follicular |
4.627600E-01 |
| Tall-VS-Other |
5.353000E-01 |
| Tall-VS-Normal |
2.48209999997862E-06 |
| Follicular-VS-Other |
8.641000E-01 |
| Follicular-VS-Normal |
3.4884999999818E-06 |
| Other-VS-Normal |
3.469800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.61884999999584E-05 |
| Normal-vs-N1 |
1.93749999999326E-06 |
| N0-vs-N1 |
2.564800E-01 |
|
|
